# US 2020/0299234 A1 · Compositions for treating neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0299234 A1
- Document ID: US20200299234A1
- Status: Published application
- Kind: A1
- Application number: 16/613,697
- Filed: 2018-05-15
- Published: 2020-09-24
- Earliest claimed: 2017-05-15
- Assignees: Cognition Therapeutics, Inc.
- Applicants: Cognition Therapeutics, Inc.
- Inventors: Gilbert M. RISHTON; Gary C. LOOK; Susan M. CATALANO
- Web page: https://patentgrep.com/patent/US20200299234A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 295/192: from aromatic carboxylic acids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 211/27: having amino groups linked to the six-membered aromatic ring by saturated carbon chains
- C07C 217/46: the carbon skeleton being acyclic and unsaturated
- C07C 309/04: containing only one sulfo group
- C07C 309/14: containing amino groups bound to the carbon skeleton
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/06: having no double bonds between ring members or between ring members and non-ring members
- C07D 211/22: by oxygen atoms
- C07D 211/30: with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 211/62: attached in position 4
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- C07D 265/30: not condensed with other rings
- C07D 295/06: substituted by halogen atoms or nitro radicals
- C07D 295/08: substituted by singly bound oxygen or sulfur atoms
- C07D 295/18: by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 295/185: from aliphatic carboxylic acids
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 405/02: containing two hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.

## Claims

### Claim 1

A compound of Formula I or pharmaceutically acceptable salt thereof:
wherein:
each of Ra, Rb, Rc, Rd and Re is independently selected from the group consisting of, H, hydroxyl, halo, alkyl, alkoxy, CF3, SO2CH3, and morpholino;
R1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH═C(CH3)2; and
R2 is an optionally substituted cyclic amino group.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of optionally substituted aziridinyl, optionally substituted pyrrolidinyl, optionally substituted imidizolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted oxopiperazinyl, and optionally substituted morpholinyl.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R2 is optionally substituted piperidinyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of
wherein:
R3 is selected from the group consisting of hydrogen and C1-C8 alkyl;
R4 is selected from the group consisting of hydrogen, hydroxyl, halo, CF3, alkoxy, aryloxy, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl, optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl; and
each of R5 and R6 is independently selected from the group consisting of hydrogen, hydroxyl, sulfonyl, dialkylamino, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl, optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of:
wherein R3a selected from the group consisting of hydrogen and C1-C8 alkyl; and n is an integer selected from 0, 1 and 2.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R2 is selected from

### Claim 7 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of:
wherein R7 is selected from the group consisting of hydrogen, hydroxyl, sulfonyl, dialkylaminosulfonyl, alkoxycarbonyl, acyl, benzoyl, cycloalkylcarbonyl, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl, optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is:
wherein R8 is hydrogen, hydroxyl, sulfonyl, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl; optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of

### Claim 10 (depends on 1)

The compound of claim 1, wherein R2 is bicyclic.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of
wherein R9 is, independently selected from the group consisting of hydrogen, hydroxyl, sulfonyl, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl, optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl.

### Claim 12 (depends on 1)

A compound of claim 1 selected from the groups consisting of:
or pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 14

A compound selected from the group consisting of
or a pharmaceutically acceptable sat thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15 wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 15)

A method of treating Alzheimer's disease comprising administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition according to claim 15.

### Claim 18 (depends on 15)

A method for inhibiting cognitive decline in a subject exhibiting, or at risk of exhibiting, cognitive decline, comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 15.

### Claim 19 (depends on 15)

A method of inhibiting amyloid beta effect on a neuronal cell comprising administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition according to claim 15.

### Claim 20 (depends on 15)

A method of treating mild cognitive impairment in Alzheimer's disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 15.

### Claim at position 21

-27. (canceled)
